NCT00069277View on ClinicalTrials.gov

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Cancer
Interventions
DRUG

E7389

Trial Locations (3)

90025

Cancer Institute Medical Group, Los Angeles

90404

Premiere Oncology, Santa Monica

08901

New Brunswick

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00069277 - Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter